SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending as the community rallies around the acronym's meaning: 'We All Gonna Make It,' expressing strong conviction and optimism. The crypto, built on the $SOL.X Solana blockchain and launched on $PUMP.X, is fostering a culture of perseverance and community spirit, attracting attention as a potential 'legacy play' in the meme coin space.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community anticipates a significant token burn event when the project reaches 2000 watchers. Community members are actively discussing the coin's resilience during market dips and its potential for future growth, emphasizing the strength of the community and ongoing development efforts. Amidst a volatile crypto market, Brokecoin holders are touting the project's transparency and commitment to long-term value.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to the announcement that its Black Widow drone system has been approved and added to the NATO Support and Procurement Agency catalog, a move seen as a significant step towards potential contracts and revenue. The community is actively discussing the implications of this approval, with some expressing optimism about future growth and others remaining cautious until actual purchase orders are secured. Broader discussions include comparisons to other drone companies and the potential impact on the defense sector.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to a recently announced $750 million ATM offering, which the community is interpreting in several ways: some believe it's a strategic move to fund acquisitions or secure large government contracts, while others worry about potential dilution and delayed timelines for the Neutron rocket; despite differing opinions, many view it as a sign of growth and opportunity, especially given the company's position in the expanding space sector.

Nukkleus, Inc. is a financial technology company, which engages in the provision of blockchain-enabled technology solutions. It also offers software and technology solutions for worldwide crypto and foreign exchange transactions with a focus on the movement of funds via crypto rails and back-to-back access to fiat conversion in a compliant regulated fashion. It operates through the following geographical segments: United States, United Kingdom, and Malta. The company was founded on May 24, 2019 and is headquartered in New York, NY.

Nukkleus Inc - Ordinary Shares - New

Nukkleus Inc

Nukkleus Inc. is trending due to its acquisition of Titan Software Engineering, a move into the defense AI market, sparking community discussion around the company's strategic shift and potential growth; many traders are watching for a sustained breakout, while others express concerns about cash position and potential dilution. The stock's volatility and past pumps are also driving conversation as traders weigh the risks and opportunities.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle's stock is trending amid discussions about a recent share repurchase authorization and its potential impact. Some investors view the buyback as a positive signal, while others believe the funds could be better allocated to initiatives like AI or expansion, particularly in Asia. Community sentiment appears mixed, with some anticipating a short squeeze and others highlighting concerns about insider selling and broader economic factors.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is trending downwards following disappointing earnings, with a profit plunge and revenue miss driving negative sentiment. The community is concerned about declining same-store sales and a weak consumer environment, questioning the company's future. Some are speculating about a potential acquisition or bankruptcy, while others hope for a turnaround under the new CEO.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending amid growing interest in nuclear energy's role in powering AI data centers, further fueled by a new facility announcement and positive analyst coverage. Community discussions revolve around the company's future growth potential versus valuation concerns, especially as it remains pre-revenue. The stock's volatile price action sparks debates on long-term prospects amid broader sector tailwinds.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as it approaches all-time highs, with community members closely watching for a breakout above the $97-$100 range. Bullish sentiment is fueled by the company's inclusion in the S&P 100, a recent investment from Lucid Motors, and expansion into new sectors like train travel and retail delivery, though some analysts cite concerns about labor regulations and competition from autonomous vehicles.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla $TSLA is trending as traders discuss Elon Musk's recent $1 billion stock purchase and its impact on the stock's momentum. The community is debating whether this is a vote of confidence or a manipulation tactic, while also eyeing potential catalysts such as robotaxi developments and future AI advancements. Overall sentiment seems to be mixed, some seeing potential for the stock to reach new highs while others stay cautious.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Shares of Ocular Therapeutix (OCUL) plunged nearly 17% on Monday, marking their steepest single-day decline since April, as the biotech firm's fourth-quarter earnings missed expectations. The stock extended losses in after-hours trading.The company posted Q4 revenue of $17.08 million, slightly below analysts' estimates of $17.16 million. While its quarterly loss narrowed to $0.29 per share from $0.35 a year earlier, it still came in wider than the Street's forecast of $0.27 per share.Ocular also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet age-related macular degeneration (wet AMD), shifting the timeline from Q4 2025 to Q1 2026. The adjustment follows FDA approval of study protocol changes under a Special Protocol Agreement (SPA).Despite the earnings disappointment and trial delay, Ocular reaffirmed its financial stability, reporting a cash balance of $392.1 million as of Dec. 31, 2024, which it expects to fund operations into 2028 without the need for additional capital raises this year.Retail sentiment on Stocktwits flipped to 'bullish' from 'bearish' amid the sell-off, with message volume surging 2,200% by the end of Monday's regular session.<figure class="image"><img style="aspect-ratio:1316/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/OCUL_sentiment_and_message_meter_as_of_March_3_4b0b51c1ff.png" alt="OCUL sentiment and message meter as of March 3.png" width="1316" height="316"><figcaption>OCUL sentiment and message meter as of March 3 | source: Stocktwits</figcaption></figure>One trader argued that selling the stock now could mean missing a long-term payoff, setting a personal price target of $25 — implying a potential 500% upside from the last close.&nbsp;<stembedurl>https://stocktwits.com/WaterskiUP/message/606602356</stembedurl>Another investor expressed optimism but questioned why the company didn't provide updated enrollment figures for its SOL-R (Phase 3, wet AMD) trial or 2025 revenue guidance for Dextenza, an FDA-approved corticosteroid for post-surgical inflammation and allergic conjunctivitis.<stembedurl>https://stocktwits.com/esu89/message/606599224</stembedurl>Ocular modified its SOL-R trial protocol, reducing the number of randomized subjects from 825 to 555, citing "strong" ongoing enrollment. As of Jan. 10, 2025, 311 subjects had been enrolled across various stages in the U.S. and South America.<a href="https://stocktwits.com/symbol/OCUL">OCUL stock</a> has tumbled more than 31% year-to-date.&nbsp;Wall Street analysts remain bullish — of the nine analysts covering the stock, five rate it a 'Buy,' while four call it a 'Strong Buy,' according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling.

Ocular Therapeutix Stock Sees Worst Day In Nearly A Year On Q4 Miss, But Retail Sees A Comeback

The company also announced a delay in releasing late-stage trial data for axpaxli, its experimental treatment for wet AMD, shifting the timeline from Q4 2025 to Q1 2026.

Equity

Optimistic Buy Rating for Ocular Therapeutix Amid Promising Axpaxli Trials and Strategic Execution

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Ocular Therapeutix (OCUL Research Report), with a pr...

Shares of 4D Molecular Therapeutics Inc. (FDMT) plummeted over 35% to $17.30 by Wednesday afternoon, marking it as the top loser among U.S. stocks. Surprisingly, retail traders remain highly bullish on the stock, with Stocktwits sentiment extremely bullish (85/100) amid extremely high message volumes (95/100).<figure class="image"><img style="aspect-ratio:1308/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_Sentiment_Meter_On_Jul_17_5f2f85024d.png" alt="FDMT Stocktwits Sentiment Meter On Jul 17" width="1308" height="308"><figcaption>FDMT Stocktwits Sentiment Meter On Jul 17</figcaption></figure>Initially, FDMT shares climbed following the release of encouraging mid-stage clinical study results for its 4D-150 gene therapy, aimed at treating wet age-related macular degeneration (wAMD), a chronic eye disorder that leads to blurred vision or blind spots in central vision.However, the broader market turned its focus to various downside risks, including safety concerns raised by RBC Capital. While the firm maintains 4D-150 is "best in class," it flagged a "safety blip" – one case of inflammation in a patient with a history of syphilis, Investing.com <a href="https://in.investing.com/news/stock-market-news/4d-molecular-therapeutics-tumbles-following-midstage-clinical-study-results-432SI-4316187">reported</a>. BMO Capital lowering the price target further may have added to the pressure.Despite the sell-off, retail investors on Stocktwits seem to view Wednesday’s crash as a buying opportunity. One user noted that 4D’s peers, Ocular Therapeutix Inc. (OCUL), Adverum Biotechnologies Inc (ADVM) and EyePoint Pharmaceuticals Inc. (EYPT), “are taking it on the chin today.”“Obviously, Nasdaq taking it hard today as well. &nbsp;Perhaps, just a general opinion of overvaluation and market fatigue? &nbsp;Very odd stock movement to me, I do expect it will reverse soon,” said Stocktwits user ‘<a href="https://stocktwits.com/ehschunk/message/579821570">ehschunk</a>’.<figure class="image"><img style="aspect-ratio:1318/454;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FDMT_stocktwits_comment_Jul_17_88b7f49b68.png" alt="Stocktwits user ehschunk's post on FDMT stream" width="1318" height="454"><figcaption>Stocktwits user ehschunk's post on FDMT stream</figcaption></figure>The overall market sentiment didn’t help, as U.S. stocks pulled back from their all-time highs on Wednesday, impacted by falling chip and tech stocks, though the Dow Jones managed its sixth consecutive day of gains.FDMT shares are down over 19% year-to-date, contrasting with OCUL’s impressive 65% rise. EYPT has had an even tougher year, losing 57% so far, while ADVM has lost only 0.18%.However, FDMT’s consistent performance in beating EPS estimates for the past four quarters provides some relief and hope for a rebound among its retail investors.

Wall Street’s Top Loser Today Stays In Retail’s Good Books: Stocktwits Extremely Bullish On FDMT

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics

Wall Street’s Top Loser Today Remains In Retail’s Good Books

Despite a 35% drop in shares, retail investors remain bullish on 4D Molecular Therapeutics on promising clinical study results

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix (OCUL Research Report) today and set a price target of $15.00. The...

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

US Stocks At All-Time High, Nasdaq Futures Gains For 8th Day After SNB Unexpectedly Cuts Rate

 After hitting the beach during yesterday's blistering Juneteenth holiday, the "buy...

Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)

Latest Ratings for OCUL
 DateFirmActionFromTo Mar 2022JMP SecuritiesMaintainsMarket Outperform Nov 2021JMP SecuritiesMaintainsMarket Outperform Oct 2021HC Wainwright & Co.MaintainsBuy
 View More...

Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder

Ocular Therapeutix's Phase 1 HELIOS study unveils Axpaxli's efficacy in treating non-proliferative diabetic retinopathy. Significant DRSS improvement with no worsening observed. Positive Phase 2 data...

The Analyst Verdict: Ocular Therapeutix In The Eyes Of 8 Experts

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

OCUL
Ocular Therapeutix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OCUL News

OCUL Ocular Therapeutix Inc